Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly drug shows activity across multiple cancer types
Enzastaurin is an investigational, multi-targeted therapy that is currently the focus of two global phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin’s
Enzastaurin is an investigational, multi-targeted therapy that is currently the focus of two global phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin’s
Both phase II studies – Study 6 and Study 3 – met their primary endpoint of increased progression free survival (PFS) in patients with locally advanced or metastatic
Results of the study, named IRIS, were presented at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO). Data from the study, the largest clinical
The preliminary data, which are from an interim analysis of Wyeth’s ongoing phase III clinical trial of temsirolimus (CCI-779) in advanced renal cell carcinoma (RCC), showed that single-agent
The licensing agreement follows a long-standing collaboration between both parties on GSK’s investigational MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) in non-small cell lung cancer (NSCLC). This novel cancer
Both companies will contribute expertise and intellectual property relating to JAK3 inhibitors for the purpose of bringing compounds into the clinic. Novartis will assume responsibility for product development
Panitumumab is an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr). Results from both studies suggest that the antitumor activity of panitumumab was
New data from a five-year update from the bone sub protocol of the ATAC trial confirm that women who have a normal bone mineral density (BMD) at the
The committee voted in favor of accelerated approval of the drug for the treatment of adults in all phases of chronic myeloid leukemia (CML) with resistance or intolerance
In the study, the combination of Tykerb (lapatinib ditosylate) and Roche's Xeloda (capecitabine) versus capecitabine alone nearly doubled time to progression (36.9 weeks in the combination arm versus